Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.
Yoshida Y, Yamada T, Kamiyama H, Kosugi C, Ishibashi K, Yoshida H, Ishida H, Yamaguchi S, Kuramochi H, Fukazawa A, Sonoda H, Yoshimatsu K, Matsuda A, Hasegawa S, Sakamoto K, Otsuka T, Koda K; TAS CC3 Study Group..
Yoshida Y, et al. Among authors: yoshida h.
Int J Clin Oncol. 2021 Jan;26(1):111-117. doi: 10.1007/s10147-020-01794-8. Epub 2020 Oct 21.
Int J Clin Oncol. 2021.
PMID: 33083913
Clinical Trial.